HOW TO TREAT RESISTANT BIPOLAR PATIENTS
The DSM-IV defines mixed bipolar episodes as being
relatively rare, but for those of us in clinical practice, this definition may
be too conservative to be of much use. What is a mixed bipolar episode and how
best can we treat these patients?
Welcome to the Clinician’s Roundtable. I am Dr. Leslie
Lundt, your host and with me today is Dr. Robert Post. Dr. Post is Professor
of Psychiatry at George Washington University and Penn State College of
Medicine and he heads the Bipolar Collaborative Network. For 37 years, he
worked at the NIMH, studying and treating treatment-resistant unipolar and
bipolar patients. He has won more than a dozen national and international
awards for his research. Dr. Post has just published a new book
"Treatment of Bipolar Illness: A Casebook for Clinicians And
Patients."
DR. LESLIE LUNDT:
Welcome to ReachMD, Dr. Post.
DR. ROBERT POST:
Well, thank you very much. I am very happy to be here.
DR. LESLIE LUNDT:
DR. ROBERT POST:
DR. LESLIE LUNDT:
So, thinking about maybe a primary care practitioner in the audience
listening, how might they be able to pick up these patients in their office?
DR. ROBERT POST:
Again, I think the issue is focusing in on patients having
increased energy and decreased need for sleep as to great screening questions
because even an uncomfortable, dysphoric, manic patient will answer positively
to those questions. So, it's the energy and feeling even with marked sleep
loss that they are just ready to go that those 2 components will pick up both
the euphoric patients and the dysphoric patients.
DR. LESLIE LUNDT:
DR. ROBERT POST:
Exactly, exactly.
DR. LESLIE LUNDT:
DR. ROBERT POST:
DR. LESLIE LUNDT:
If you are new to our channel, you are listening to The
Clinician’s Roundtable on ReachMD, the Channel for Medical Professionals. I am
Dr. Leslie Lundt, your host and with me today is Dr. Robert Post. We are
discussing mixed bipolar episodes.
DR. LESLIE LUNDT:
DR. ROBERT POST:
Yeah, well, in an agitated depression, the patient is
classically depressed, low, sad, hopeless, goal driven, and at the same time,
they may have a lot of hand wringing and psychomotor activation as part of that
depression, but as you pointed out, the key element here is that they are not
energized and they don't have a decreased need for sleep. They may be
insomniac, but they wish they could be sleeping as opposed to a dysphoric manic
patient, who even on a few hours of sleep is ready to go.
DR. LESLIE LUNDT:
DR. ROBERT POST:
DR. LESLIE LUNDT:
Thinking about the mood stabilizers, then can you give us a
quick rundown on the mood stabilizers that would be appropriate in these
patients?
DR. ROBERT POST:
Yeah, again lithium often needs some extra help with the
other ones and lamotrigine or Lamictal, carbamazepine or Tegretol, or valproate
or Depakote, those are the other anticonvulsant mood stabilizers. Each of
those seems to be helpful in the anxious components and some of the dysphoric
components of the illness; and now we are increasingly seeing that the atypical
antipsychotics also have very good antidepressant, anti-anxiety effects and for
example, quetiapine or Seroquel is actually now FDA approved as monotherapy for
the bipolar depression so that those are very good adjunctive approaches to the
patients with mixed mania.
DR. LESLIE LUNDT:
DR. ROBERT POST:
Perhaps, I think it relates to the comfort level of the
treating physician if they are really on top of it and comfortable with dealing
with these other agents that actually can be helpful for them either to be
involved somewhat or primarily involved because so many of these medications
have side effects and so many medical illnesses are co-occurring with
depression. For example, patients are twice as likely to have a heart attack
and die of it if they are depressed than if they are not. All sorts of
illnesses, medical illnesses are much more common and/or difficult to treat in
the context of depression. So, having a primary care doc either closely
involved or if they are comfortable actually treating the illness is I think a
good idea.
DR. LESLIE LUNDT:
If I look at the list of mood stabilizers, including
lithium, there are some pretty nasty possible side effects and some fairly
intense monitoring that needs to be done – if we think of Tegretol of course we
have to worry about getting CBCs and looking for aplastic anemia; Depakote, the
risk of pancreatitis, polycystic ovaries, liver disease. None of them are
clean without significant problems that I can see.
DR. ROBERT POST:
DR. LESLIE LUNDT:
Can you give us some suggestions about dealing with the
atypical antipsychotics, lot of worry about the weight gain and possible lipid
and metabolic consequences of using drugs in this category?
DR. ROBERT POST:
Yeah, this is a definite problem and one of the approaches
that I have taken is actually to try to use some of the more difficult to
titrate drugs first that has a better profile for less weight gain and less
metabolic problems that is aripiprazole (Abilify) or ziprasidone (Geodon).
Those are pretty weight neutral in adults compared to moderate weight gain with
quetiapine or Seroquel or risperidone. Olanzapine (Zyprexa) and Clozapine are
sort of the worst offenders. So that if one is going to use an atypical is
trying to use some of the better tolerated ones in preference for ones that can
be more problematic.
DR. LESLIE LUNDT:
Any suggestions on dosing? I know many of us have had a
hard time with aripiprazoleand ziprasidone just trying to figure out
how the dose is.
DR. ROBERT POST:
Yeah, I think I had that problem in the beginning where I
tried pretty hefty doses right from the get-go and patients did not like me
whatsoever; and I think the thing to do is to actually start with baby doses,
start everybody with 1 or 2 mg of aripiprazole and then titrate slowly
according to side effects tolerability and particularly now that aripiprazole
is approved as an adjunct for unipolar depression, starting it low in those
patients is quite important. The story with the ziprasidone or Geodon is a
little bit more complicated and it actually may be that higher doses achieve
fairly rapidly, may be less activating as one brings in some of the other
mechanisms of action of the drug at slightly higher doses, but both of those
drugs require a little care in the approach to the patient as opposed to some
of the other ones that are much easier to deal with.
DR. LESLIE LUNDT:
Well, it's certainly a confusing and difficult topic, but
thank you for enlightening us today.
DR. ROBERT POST:
Thank you.
DR. LESLIE LUNDT:
We have been speaking
with Dr. Robert Post, the author of “Treatment of Bipolar Illness: A Casebook for
Clinicians And Patients.” We have been talking about managing mixed bipolar
states.
I am Dr. Leslie Lundt. You have been listening to the
Clinician’s Roundtable on ReachMD XM157, the Channel for Medical
Professionals. Thank you for listening.